In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

The group was led by Casdin Capital, which surged 16 percent last month, according to an investor. This puts its share class that invests only in public securities up more than 40 percent for the year ...

To celebrate Science Week and the theme of regeneration, we ask an expert in the field of cell therapy everything you might ...

Me, the genetics startup that has repeatedly captured the public imagination and then faced nearly fatal business challenges, ...

In a report released on November 7, Jonathan Chang from Leerink Partners reiterated a Buy rating on Revolution Medicines (RVMD – Research ...

Revolution Medicines (NASDAQ:RVMD – Free Report) had its target price increased by Needham & Company LLC from $61.00 to $68.00 in a report issued on Thursday morning,Benzinga reports. They currently ...

Stifel Nicolaus analyst Benjamin Burnett maintained a Buy rating on Revolution Medicines (RVMD – Research Report) on November 8 and set a ...

On Friday, Revolution Medicines Inc (RVMD) stock saw a modest uptick, ending the day at $60.44 which represents a slight increase of $1.34 or 2.27% from the prior close of $59.1. The stock opened at ...

Revolution Medicines Inc's commitment to precision oncology positions it at the forefront of targeted cancer therapies.

Revolution Medicines, Inc. (NASDAQ: RVMD) Q3 2024 Earnings Call Transcript November 6, 2024 Revolution Medicines, Inc. misses on earnings expectations. Reported EPS is $-0.94 EPS, expectations were ...